{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:19Z","timestamp":1791461359450,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41440-022-00922-3","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T03:36:34Z","timestamp":1652844994000},"page":"1147-1153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact of renin\u2013angiotensin\u2013aldosterone system inhibitors on COVID-19"],"prefix":"10.1038","volume":"45","author":[{"given":"Yasushi","family":"Matsuzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"922_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380 e8.","journal-title":"Cell"},{"key":"922_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.bbrc.2004.03.154","volume":"317","author":"M Surjit","year":"2004","unstructured":"Surjit M, Liu B, Kumar P, Chow VT, Lal SK. The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain. Biochem Biophys Res Commun. 2004;317:1030\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"922_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/CS20200363","volume":"134","author":"RM Touyz","year":"2020","unstructured":"Touyz RM, Li H, Delles C. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci. 2020;134:747\u201350.","journal-title":"Clin Sci"},{"key":"922_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.7150\/ijbs.57802","volume":"17","author":"Q Tang","year":"2021","unstructured":"Tang Q, Wang Y, Ou L, Li J, Zheng K, Zhan H, et al. Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation. Int J Biol Sci. 2021;17:1925\u201339.","journal-title":"Int J Biol Sci"},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1050-1738(02)00233-5","volume":"13","author":"GY Oudit","year":"2003","unstructured":"Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13:93\u2013101.","journal-title":"Trends Cardiovasc Med"},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","volume":"128","author":"K Kuba","year":"2010","unstructured":"Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010;128:119\u201328.","journal-title":"Pharmacol Ther"},{"key":"922_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1253\/circj.CJ-12-1544","volume":"77","author":"K Kuba","year":"2013","unstructured":"Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77:301\u20138.","journal-title":"Circ J"},{"key":"922_CR8","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation"},{"key":"922_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpu086","volume":"28","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28:15\u201321.","journal-title":"Am J Hypertens"},{"key":"922_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020\u20136.","journal-title":"JAMA Cardiol."},{"key":"922_CR11","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","volume":"43","author":"H Kai","year":"2020","unstructured":"Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648\u201354.","journal-title":"Hypertens Res"},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41440-022-00893-5","volume":"45","author":"E McFarlane","year":"2020","unstructured":"McFarlane E, Linschoten M, Asselbergs FW, Lacy PS, Jedrzejewski D, Williams B, et al. The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19. Hypertens Res. 2022;45:834\u201345. https:\/\/doi.org\/10.1038\/s41440-022-00893-5.","journal-title":"Hypertens Res"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","volume":"43","author":"Y Matsuzawa","year":"2020","unstructured":"Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, et al. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res. 2020;43:1257\u201366.","journal-title":"Hypertens Res"},{"key":"922_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1001\/jama.1996.03530350034031","volume":"275","author":"SK Inouye","year":"1996","unstructured":"Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275:852\u20137.","journal-title":"JAMA"},{"key":"922_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00401-010-0674-1","volume":"119","author":"J Cerejeira","year":"2010","unstructured":"Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119:737\u201354.","journal-title":"Acta Neuropathol"},{"key":"922_CR17","doi-asserted-by":"publisher","first-page":"586686","DOI":"10.3389\/fpsyt.2020.586686","volume":"11","author":"R Rozzini","year":"2020","unstructured":"Rozzini R, Bianchetti A, Mazzeo F, Cesaroni G, Bianchetti L, Trabucchi M. Delirium: clinical presentation and outcomes in older COVID-19 patients. Front Psychiatry. 2020;11:586686.","journal-title":"Front Psychiatry"},{"key":"922_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"922_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9:757\u201360.","journal-title":"Emerg Microbes Infect"},{"key":"922_CR20","doi-asserted-by":"publisher","unstructured":"Callea A, Conti G, Fossati B, Carassale L, Zagaria M, Caporotundo S, et al. Delirium in hospitalized patients with COVID-19 pneumonia: a prospective, cross-sectional, cohort study. Intern Emerg Med. 2022. https:\/\/doi.org\/10.1007\/s11739-022-02934-w.","DOI":"10.1007\/s11739-022-02934-w"},{"key":"922_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/ageing\/afab103","volume":"50","author":"SC Shao","year":"2021","unstructured":"Shao SC, Lai CC, Chen YH, Chen YC, Hung MJ, Liao SC. Prevalence, incidence and mortality of delirium in patients with COVID-19: a systematic review and meta-analysis. Age Ageing. 2021;50:1445\u201353.","journal-title":"Age Ageing"},{"key":"922_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s41999-020-00353-8","volume":"11","author":"BC McLoughlin","year":"2020","unstructured":"McLoughlin BC, Miles A, Webb TE, Knopp P, Eyres C, Fabbri A, et al. Functional and cognitive outcomes after COVID-19 delirium. Eur Geriatr Med. 2020;11:857\u201362.","journal-title":"Eur Geriatr Med."},{"key":"922_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccc.2020.08.009","volume":"37","author":"MC Duggan","year":"2021","unstructured":"Duggan MC, Van J, Ely EW. Delirium assessment in critically ill older adults: considerations during the COVID-19 pandemic. Crit Care Clin. 2021;37:175\u201390.","journal-title":"Crit Care Clin"},{"key":"922_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","volume":"9","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275\u201384.","journal-title":"Lancet Respir Med"},{"key":"922_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros E, Silva PGM, Moll-Bernardes RJ, Dos Santos TM, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254\u201364.","journal-title":"JAMA"},{"key":"922_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","volume":"9","author":"A Bauer","year":"2021","unstructured":"Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021;9:863\u201372.","journal-title":"Lancet Respir Med"},{"key":"922_CR27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ajh\/hpab111","volume":"34","author":"F Najmeddin","year":"2021","unstructured":"Najmeddin F, Solhjoo M, Ashraf H, Salehi M, Rasooli F, Ghoghaei M, et al. Effects of renin-angiotensin-aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: a randomized triple-blind clinical trial. Am J Hypertens. 2021;34:1217\u201326.","journal-title":"Am J Hypertens"},{"key":"922_CR28","doi-asserted-by":"publisher","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","volume":"37","author":"MA Puskarich","year":"2021","unstructured":"Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine. 2021;37:100957.","journal-title":"EClinicalMedicine"},{"key":"922_CR29","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","volume":"37","author":"M Duarte","year":"2021","unstructured":"Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of COVID-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962.","journal-title":"EClinicalMedicine"},{"key":"922_CR30","doi-asserted-by":"publisher","first-page":"e043625.","DOI":"10.1136\/bmjopen-2020-043625","volume":"11","author":"SR Gnanenthiran","year":"2021","unstructured":"Gnanenthiran SR, Borghi C, Burger D, Charchar F, Poulter NR, Schlaich MP, et al. Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. BMJ Open. 2021;11:e043625.","journal-title":"BMJ Open"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00922-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T12:16:20Z","timestamp":1675599380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00922-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-00922-3","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}